secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017192
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics Q2 net loss $14.6M; discontinues ETX-810 Phase 2a after failure
--------------------------------------------------------------------------------

- Net loss of $14.6M for Q2 2022 vs $8.7M in Q2 2021; cash, equivalents, securities $134.7M.
- ETX-810 discontinued after failing primary endpoint in lumbosacral radicular pain Phase 2a.
- Initiated Phase 1 PK trial for ETX-155; results expected Q4 2022; Phase 2a MDD planned Q1 2023.
- Cash runway now expected to fund operations into 2025 due to ETX-810 discontinuation.
- R&D expenses $8.8M (up from $5.8M YoY); G&A $4.9M (up from $2.9M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/0000950170-22-017192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022017192/elym-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer